title: Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients.
abstract: OBJECTIVE
  To assess the prevalence and factors associated with significant hepatic steatosis (SHS, steatosis involving ≥10% hepatocytes) in HIV-infected patients.
  
  
  METHODS
  A prospective, cross-sectional study.
  
  
  METHODS
  Five hundred and five HIV-infected patients were included in this study. All patients underwent a transient elastography examination with the controlled attenuation parameter (CAP). SHS was defined using the previously identified CAP cut-off of 238 dB/m. We analysed the associations between SHS and demographics, metabolic data, coinfections and drug therapy.
  
  
  RESULTS
  SHS was detected in 201 (40%) patients. Individuals with and without plasma HIV RNA of 50 copies/ml or less presented SHS in 168 (42%) and 33 (31%) cases, respectively (P = 0.030). Patients with SHS compared with those without SHS presented higher median (IQR) BMI [BMI, 25.6 (22.5-28) vs. 22.3 (20.3-24.2) kg/m; P < 10], DBP [79 (72-85) vs. 74 (68-81) mmHg; P = 0.0001], fasting plasma glucose [95 (87-106) vs. 91 (84-97) mg/dl; P = 0.002] and triglycerides [128 (92-189) vs. 109 (80-167) mg/dl; P = 0.002], and lower HDL cholesterol [44 (37-54) vs. 48 (40-59), mg/dl; P = 0.004]. In multivariate analysis, the only factor associated with SHS was BMI [per unit increase, adjusted odds ratio (95% confidence interval) 1.34 (1.22-1-47); P < 10].
  
  
  CONCLUSIONS
  SHS measured by CAP is highly prevalent among HIV-infected patients. High BMI is the main predictor of SHS in this setting.
authors.affiliation: aHospital Universitario de Valme, Seville bHospital Universitario La Paz, Madrid cHospital Universitario Germans Trias i Pujol, Badalona dHospital General Universitario de Valencia, Valencia eHospital Universitario 12 de Octubre fAbbVie, S.L.U, Madrid, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Macías
authors.forename: Juan
authors.initials: J
authors.lastname: González
authors.forename: Cristina
authors.initials: C
authors.lastname: Tural
authors.forename: Enrique
authors.initials: E
authors.lastname: Ortega-González
authors.forename: Federico
authors.initials: F
authors.lastname: Pulido
authors.forename: Rafael
authors.initials: R
authors.lastname: Rubio
authors.forename: Celia
authors.initials: C
authors.lastname: Cifuentes
authors.forename: Marta
authors.initials: M
authors.lastname: Díaz-Menéndez
authors.forename: Antoni
authors.initials: A
authors.lastname: Jou
authors.forename: Purificación
authors.initials: P
authors.lastname: Rubio
authors.forename: Angel
authors.initials: A
authors.lastname: Burgos
authors.forename: Juan A
authors.initials: JA
authors.lastname: Pineda
mesh_terms: D000328:Adult; D015415:Biomarkers; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D054459:Elasticity Imaging Techniques; D005234:Fatty Liver / Q000175:diagnosis / Q000453:epidemiology* / Q000473:pathology*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D015415:Biomarkers